Gossamer Bio Receives Nasdaq Delisting Notice for Non-Compliance with Minimum Bid Price Requirement

San Diego, CA, April 9, 2026 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, announced today that it has received a written notice from the Listing Qualifications Department of the Nasdaq Stock Market (Nasdaq), regarding non-compliance with Nasdaq’s minimum bid price requirement.

Key Points for Investors

• Notice of Delisting: On April 8, 2026, Gossamer Bio received a written notice from Nasdaq stating that its common stock, with a par value of \$0.0001 per share, did not maintain a minimum bid price of \$1.00 per share for 30 consecutive business days, from February 24, 2026 through April 7, 2026.
• Immediate Delisting Not Triggered: This notice does not result in the immediate delisting of Gossamer’s common stock from the Nasdaq Global Select Market.
• Compliance Period: The company has 180 calendar days (until October 5, 2026) to regain compliance with the minimum bid price requirement.
• Regaining Compliance: To regain compliance, the closing bid price of Gossamer’s common stock must be at least \$1.00 per share for a minimum of ten consecutive business days before the compliance deadline.
• Potential for Additional Compliance Period: If Gossamer does not regain compliance by October 5, 2026, it may be eligible for an additional 180-day compliance period if it transfers its listing to the Nasdaq Capital Market and meets other listing requirements, except for the minimum bid price. The company must also notify Nasdaq in writing of its intention to cure the deficiency, potentially through a reverse stock split.
• Possible Delisting Outcome: If the company cannot demonstrate a credible plan to regain compliance, or if it fails to meet other listing standards, Nasdaq staff may initiate delisting proceedings. The company would have the right to appeal any such decision to a Nasdaq Hearing Panel. There is no assurance that any appeal would be successful.

Implications for Shareholders

• Share Price Sensitivity: This notice is a significant event that could impact investor confidence and share price volatility. Delisting from Nasdaq may limit the liquidity and trading volume of Gossamer Bio’s shares and could affect institutional ownership.
• Potential Corporate Actions: To regain compliance, Gossamer Bio may consider strategic options, including a reverse stock split, which could have direct implications for the share price and the number of shares outstanding.
• Ongoing Monitoring: The company stated its intention to monitor the closing bid price and consider available options to regain compliance. However, there is no guarantee that the company will be able to meet Nasdaq’s requirements within the timeframe.
• No Immediate Change in Listing Status: As of the notice date, Gossamer Bio’s shares continue to trade on the Nasdaq Global Select Market under the symbol “GOSS.”

Corporate Details

Company Name: Gossamer Bio, Inc.
Trading Symbol: GOSS
Exchange: Nasdaq Global Select Market
Address: 3115 Merryfield Row, Suite 120, San Diego, CA 92121
Phone: (858) 684-1300
Fiscal Year End: December 31
Industry: Pharmaceutical Preparations (SIC 2834)

Signature

Signed by: Christian Waage
Title: Executive Vice President, Technical Operations & Administration
Date: April 9, 2026

Investor Takeaways

• This notification is a material event that may impact the company’s share price and investor sentiment.
• Shareholders should closely monitor future announcements from Gossamer Bio regarding compliance efforts, potential corporate actions (such as a reverse stock split), and any updates on Nasdaq listing status.
• Investors should consider the risks associated with potential delisting, including reduced liquidity and possible impairment of share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors are urged to conduct their own due diligence and consult with their financial advisors before making any investment decisions. The information above is based on public filings and may be subject to change or updates by Gossamer Bio, Inc. or regulatory authorities.

View Gossamer Bio, Inc. Historical chart here